Status of work
In March, AOTMiT begins work on orders from the Minister of Health:
- Iqirvo (elafibranor) for the treatment of patients with primary biliary cirrhosis (PBC)
Justification for including the medicinal product Veyvondi for patients with von Willebrand disease types 2 and 3 in the health policy program module titled “National Program for the Treatment of Patients with Hemophilia and Related Bleeding Disorders for 2024–2028,” along with the inclusion criteria (if inclusion is justified)
The listed order is available on the AOTMiT Public Information Bulletin.